ZTS Stock Recent News
ZTS LATEST HEADLINES
Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.
Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss what the company's guidance was largely driven by, the most important aspect of Zoetis' business, and how new GLP-1 drugs could play into Zoetis' business.
Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Nathan Rich - Goldman Sachs Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Louise Chen - Cantor Operator Welcome to the Second Quarter 2023 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zoetis (ZTS) reports better-than-expected second-quarter 2023 results, beating both earnings and revenue estimates, primarily driven by the sales of its key dermatology products.
Zoetis (ZTS) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.20 per share a year ago.
When Zoetis Inc. NYSE: ZTS reports second-quarter financials next week, the market will be expecting its best revenue growth in a year and a 9% jump in profits. If history repeats, the results will be even better.
Zoetis (ZTS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zoetis: My Dog Approves Of This Dividend Compounder
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?